Floatz logo

bp1001-a

Peritoneal Cancer

Bio-Path Holdings, Inc.nucleic_acidPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

36 Active assets in the Peritoneal Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Peking University
Phase 2BB
Docetaxel
University of Pittsburgh
Phase 2BB
FLUOROURACILUM
City of Hope Medical Center
Phase 3BB
Mirvetuximab Soravtansine
AbbVie
Phase 3BB
Pembrolizumab
University College, London
Phase 2BB

View all 50 →

Same molecule, other indications

bp1001-a is also rated in:

ovarian carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
fallopian tube neoplasmDormant
CC
Indicative ·
41 / 100
View asset →
Solid Tumor, AdultDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →